Trials / Completed
CompletedNCT00509210
Study of Telaprevir in Subjects With Hepatic Impairment
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- —
- Sponsor
- Vertex Pharmaceuticals Incorporated · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to assess the safety and pharmacokinetics of Telaprevir following administration of multiple oral doses to subjects with moderate and severe hepatic impairment.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | telaprevir (VX-950) |
Timeline
- Start date
- 2007-09-01
- Primary completion
- 2008-06-01
- Completion
- 2008-06-01
- First posted
- 2007-07-31
- Last updated
- 2008-10-29
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00509210. Inclusion in this directory is not an endorsement.